Shots: The P-III PSOARING 3 LTE study evaluates tapinarof (1%, qd) vs vehicle-controlled cream in 763 patients with PsO for ~40wks. & a 4wks. safety follow-up period The results showed […]readmore
Tags : Tapinarof
Shots: The first patient has been dosed in a P-III program that consists of P-III ADORING 1/2 and long-term extension ADORING 3 study evaluates the safety and efficacy of tapinarof […]readmore
Shots: The two P-III PSOARING 1 and PSOARING 2 trials involve evaluating Tapinarof (1% dosed, qd) vs vehicle (qd) in 1,025 patients aged 18-75yrs. with plaque psoriasis Results: 2EPs & […]readmore
Shots: The P-III PSOARING 3 is an OLE study assessing Tapinarof (1%) in patients with plaque psoriasis for ~40wks. and a 4wks. safety follow-up period The interim analyses showed 57.3% […]readmore
Shots: The pivotal P-III clinical program for tapinarof in adult with PsO consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980) PSOARING 3 (NCT04053387), an ongoing long-term safety study. Positive […]readmore
Shots: Dermavant to receive $60M up front, up to $53M as development milestones and royalties on sales of the tapinarof in psoriasis and AD. JT and its subsidiary, Torii Pharmaceutical […]readmore